SCHEMBL14027355

SCHEMBL14027355

Cc1ccnc(Nc2ccccc2S(=O)(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 2/20 0.56
JAK2 O60674 1/20 0.56
JAK1 P23458 1/20 0.56
KCNH2 Q12809 1/20 0.56
KDM4E B2RXH2 5/20 0.48
ALDH1A1 P00352 4/20 0.48
HPGD P15428 1/20 0.48
LMNA P02545 3/20 0.47
MAPK10 P53779 1/20 0.47
GLA P06280 1/20 0.45
ATM Q13315 1/20 0.45
POLB P06746 1/20 0.44
KCNN1 Q92952 1/20 0.43
KCNN2 Q9H2S1 1/20 0.43
KCNN3 Q9UGI6 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDR P35968 2/20 0.43
KMT2A Q03164 1/20 0.43
MAP4K4 O95819 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14027359 0.83 NPC1 (0.42) TYK2JAK2JAK1KCNH2KDM4E
SCHEMBL31247722 0.81 TYK2 (0.63) TYK2JAK2JAK1KCNH2KDM4E
SCHEMBL23746304 0.75 TTR (0.54) KDM4EALDH1A1HPGDLMNAPOLB
SCHEMBL23746653 0.74 MAPT (0.54) KDM4EALDH1A1HPGDGLAPOLB
SCHEMBL4941362 0.74 MAPK10 (0.71) JAK2KDM4EALDH1A1HPGDLMNA
SCHEMBL13980041 0.73 GAA (0.42) KDM4EALDH1A1HPGDLMNAPOLB
SCHEMBL5778360 0.72 KMT2A (0.49) LMNAMAPK10POLBKCNN1KCNN2
SCHEMBL23746676 0.72 NPSR1 (0.53) KDM4EALDH1A1HPGDLMNAPOLB
SCHEMBL7076426 0.72 MAPT (0.63) KDM4EALDH1A1HPGDLMNAGLA
SCHEMBL2912518 0.72 KDR (0.57) KDM4EALDH1A1POLBKCNN1KCNN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255091-A1 COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS ASTRUM THERAPEUTICS PTY LTD. (AU) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255091-A1 COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS IAPP, BCL2, AMY2A TYK2 4162/4885JAK2 2716/4885JAK1 4637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.